
Docket No.: PF-0163-2 DIV

"Express Mail" mailing label number <u>EL 856 153 389 US</u>. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on <u>4000</u>.



Printed: <u>Teodoro Martinez</u>



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bandman et al.

Title:

HUMAN SELENIUM-BINDING PROTEIN

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 08/749,903, filed November 15, 1996 from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

76909

Docket No.: PF-0163-2 DIV

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108.** A duplicate copy of this communication is enclosed.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: <u>April 24,2001</u>

Kusa K. Nathe

Susan K. Sather Reg. No. 44,316

Direct Dial Telephone: (650) 845-4646

3160 Porter Drive Palo Alto, California 94304 Phone: (650) 855-0555

Fax: (650) 845-4166

76909

U.S. Depart	ment	of Commerce,	Patent and T	ent and Trademark Office		Atty Docket No.		Serial No.	
					PF-0163-2 DIV		To Be A	To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS					Applicant .				
(Use several sheets if necessary)					Bandman et al.				
					Filing Date Gro		Group	- T	
					Herewith		841		
			U.S.	Patent Documents			973 09/	04,	
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing D		
			Foreign	n Patent Documents					
			rorergi	racere bocamere.	<u> </u>		Transl	ation	
		Document	Date	Country	Class	Subclass	Yes	No	
				2.2.3.2.2					
	ОТН	ER ART (In	cluding Auth	or, Title, Date,	Pertinen	t Pages, Et	cc.)		
	1	Knekt et al., "Serum Selenium and Subsequent Risk of Cancer Among Finnish Men and Women," Journal of National Cancer Institute, 82(10):864-868 (1990)							
	2	Handel et al., "Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos," Proc. Natl.Acad. Sci. USA , 97:4497-4501 (1995)							
	3	Bansal, "DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention," Carcinoqenesis , 11(11):2071-2073 (1990) (GI 227630)							
	4	Bartolone et al., "Purification, Antibody Production, and Partial Amino Acid Sequence of the 58-kDa Acetaminophen-Binding Liver Proteins," <u>Toxicology and Applied Pharmacology</u> , 113:19-29 (1992)							
	5	Lanfear et al., "Different patterns of regulation of the genes encoding the closely related 56 kDA selenium-and acetaminophen-binding proteins in normal tissues and during carcinogenesis," Carcinogenesis , 14(3):335-340 (1993) (GI 298710)							
	6	Ishii et al., "Significant induction of a 54-kDa protein in rat liver with homologous alignment to mouse selenium binding protein by a coplanar polychlorinated biphenyl, 3, 4, 5, 3', 4'-pentachlorobiphenyl and 3-methylcholanthrene," Toxicology Letters, 87:1-9 (1996)							
	7	Spyrou et al., "AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione," <u>FEBS Letters</u> , 368:59-63 (1995)							
	8	Morrison et al., "Intracellular 58-kd selenoprotein levels correlate with inhibition of DNA synthesis in mammary epithelial cells," Carcinogenesis , 9(10):1801-1810 (1988)							
	9	Chang et al., (GI 1374792), GenBank Sequence Database (Accession 1374792), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland 20894 (1996)							
Examiner			Date Consid	lered					

MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.